BRITISH JOURNAL OF PHARMACOLOGY

The British Journal of Pharmacology welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

Edited for the British Pharmacological Society by

A.T. Birmingham (Chairman)

R.W. Horton W.A. Large (Secretaries)

Editorial Board

P.I. Aaronson London C.J. Bailey Birmingham L. Belardinelli Gainesville, USA Maria G. Belvisi London G.W. Bennett Nottingham T.P. Blackburn Harlow M.R. Boarder Leicester N.G. Bowery Birmingham W.C. Bowman Glasgow R. Busse Frankfurt, Germany S.P. Butcher Edinburgh K.D. Butler Horsham M. Caulfield Dundee R.A.J. Challiss Leicester R. Chess-Williams Sheffield T. Cocks Melbourne, Australia Helen M. Cox London V. Crunelli Cardiff A. Dickenson London J.R. Docherty Dublin
L. Edvinsson Lund, Sweden G. Edwards Manchester R.M. Eglen Palo Alto, USA P.C. Emson Cambridge R.H. Evans Bristol A.W. Ford-Hutchinson Quebec, Canada A.C. Foster San Diego, USA J.R. Fozard Basle, Switzerland B.B. Fredholm Stockholm, Sweden Allison D. Fryer Baltimore, USA J.P. Gallagher Galveston, USA

Sheila M. Gardiner Nottingham C.J. Garland Bristol A. Gibson London M.A. Giembycz London W.R. Giles Calgary, Canada R.G. Goldie Perth, Australia R.J. Griffiths Groton, USA R.W. Gristwood Cambridge Judith M. Hall Guildford D.W.P. Hay Philadelphia, USA D.J. Heal Nottingham P.G. Hellewell London K. Hillier Southampton P. Holzer Graz, Austria S.M.O. Hourani Guildford D. Hoyer Basle, Switzerland G.W. John Castres, France E.J. Johns Birmingham R.S.G. Jones Oxford P.A.T. Kelly Edinburgh
D.A. Kendall Nottingham C. Kennedy Glasgow I. Kitchen Guildford N.R. Kitteringham Liverpool R.Z. Kozlowski Oxford S. Lazareno London R.A.J. Lefebvre Ghent, Belgium J. Llenas Barcelona, Spain A.T. McKnight Cambridge C.A. Maggi Florence, Italy I.G. Marshall Glasgow Janice M. Marshall Birmingham G. Martin Beckenham A. Mathie London P.K. Moore London H. Nilsson Aarhus, Denmark H. Osswald Tübingen, Germany F.L. Pearce London J.D. Pearson London U. Quast Tübingen, Germany A.G. Ramage London P.J. Roberts Bristol W.C. Sessa New Haven, USA N. Shankley London N.L. Simmons Newcastle P.G. Skett Glasgow P. Sneddon Glasgow S. Clare Stanford London K. Starke Freiburg, Germany R.J. Summers Melbourne, Australia J. Tamargo Madrid, Spain C. Thiemermann London
M.D. Tricklebank Basle, Switzerland T.J. Verbeuren Suresnes, France R.R. Vollmer Pittsburgh, USA Cherry L. Wainwright Glasgow T.D. Warner London K.J. Watling Boston, USA J. Westwick Bath K.I. Williams Bath V.G. Wilson Nottingham E.H.F. Wong Milan, Italy S. Wonnacott Bath B. Woodward Bath

Corresponding Editors

P.R. Adams Stony Brook, U.S.A.
C. Bell Dublin
F.E. Bloom La Jolla, U.S.A.
A.L.A. Boura Newcastle, Australia
N.J. Dun Toledo, U.S.A.
R.F. Furchgott New York, U.S.A.
T. Godfraind Brussels, Belgium
S.Z. Langer Paris, France

R.J. Miller Chicago, U.S.A.
R.C. Murphy Denver, U.S.A.
E. Muscholl Mainz, Germany
R.A. North Geneva, Switzerland
M. Otsuka Tokyo, Japan
M.J. Rand Melbourne, Australia
S. Rosell Södertalje, Sweden
P. Seeman Toronto, Canada

L. Szekeres Szeged, Hungary
B. Uvnas Stockholm, Sweden
P.A. Van Zwieten Amsterdam, Netherlands
V.M. Varagič Belgrade, Yugoslavia
G. Velo Verona, Italy
Wang Zhen Gang Beijing, China
M.B.H. Youdim Haifa, Israel

Submission of manuscripts: Manuscripts (two copies) should be sent to The Editorial Office, British Journal of Pharmacology, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE.

Authors should consult the Instructions to Authors and the Nomenclature Guidelines for Authors in Vol. 117, 389-399. These Instructions and Guidelines also appear with the journal Index for Volumes 114-116, 1995. A checklist of the essential requirements is summarised in each issue of the journal, or as the last page of the issue.

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they and the *British Pharmacological Society* wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the *British Pharmacological Society*, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

- L.M. Shuba, T. Asai, S. Pelzer & T.F. McDonald Activation of cardiac chloride conductance by the tyrosine kinase inhibitor, genistein 335
- A. Kawabata & T. Hata Attenuation by prolonged nitric oxide synthase inhibition of the enhancement of fibrinolysis caused by environmental stress in the rat

 346
- G. Kolios, D.A.F. Robertson, N.J. Jordan, A. Minty, D. Caput, P. Ferrara & J. Westwick Interluekin-8 production by the human colon epithelial cell line HT-29: modulation by interleukin-13 351
- P. Vigne, P. Pacaud, V. Urbach, E. Feolde, J.P. Breittmayer & C. Frelin The effect of PPADS as an antagonist of inositol (1,4,5)trisphosphate induced intracellular calcium mobilization 360
- F. Tomoda, R.A. Lew, A.I. Smith, A.C. Madden & R.G. Evans Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits 365
- P.S. Widdowson, M. Farnworth, R.B. Moore, D. Dunn & I. Wyatt Evidence for mediation of L-2-chloropropionic acid-induced delayed neuronal cell death by activation of a constitutive nitric oxide synthase
- H. Pickering, S. Sword, S. Vanhoff, R. Jones & D. Sugden Analogues of diverse structure are unable to differentiate native melatonin receptors in the chicken retina, sheep pars tuberalis and *Xenopus* melanophores 379
- A. Ziyyat, B.-L. Zhang & D. Benzoni Interactions between nitric oxide and prostanoids in isolated perfused kidneys of the rat 388
- A.J. Forhead, K. Whybrew, P. Hughes, F. Broughton Pipkin, M. Sutherland & A.L. Fowden Comparison of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition in pregnant sheep during late gestation 393

- A. Lindén Increased interleukin-8 release by β -adrenoceptor activation in human transformed bronchial epithelial cells 402
- I. Marshall, R.P. Burt, G.M. Green, M.B. Hussain & C.R. Chapple Different subtypes of α_{1A} -adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053
- P.D. Marley & K.A. Thomson Inhibition of nicotinic responses of bovine adrenal chromaffin cells by the protein kinase C inhibitor, Ro 31-8220 416
- R.L.C. Handy, H.L. Harb, P. Wallace, Z. Gaffen, K.J. Whitehead & P.K. Moore Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM) in vitro: antinociceptive and cardiovascular effects

 423
- E. Lilley & A. Gibson Antioxidant protection of NO-induced relaxations of the mouse anococcygeus against inhibition by superoxide anions, hydroquinone and carboxy-PTIO 432
- S.-F. Luo, C.-T. Tsai, W.-B. Wu, S.-L. Pan, Y.-J. Tsai & C.-M. Yang Pharmacological and functional characterization of bradykinin receptors in canine cultured tracheal epithelial cells

 439
- M.J. Pierce, J.A. Warner, M.R. Munday & P.T. Peachell Regulation of human basophil function by phosphatase inhibitors 446

The British Journal of Pharmacology is published by Stockton Press, a division of Macmillan Press Ltd. It is the official publication of the British Pharmacological Society.

Scope The British Journal of Pharmacology is published twice a month. It welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, Excerpta Medica, BIOSIS, CABS, CINAHL and Index Medicus.

Editorial Manuscripts (plus two copies) and all editorial correspondence should be sent to: The Editorial Office, British Journal of Pharmacology, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. Tel: +44 (0)181 767 6765; Fax: +44 (0)181 767 5645.

Advertisements Enquiries concerning advertisements should be addressed to: Michael Rowley, Hasler House, High Street, Great Dunmow, Essex CM6 1AP, UK. Tel: +44 (0)1371 874613; Fax: +44 (0)1371 872273.

Publisher All business correspondence, supplement enquiries and reprint requests should be addressed to British Journal of Pharmacology, Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526. Publisher: Marija Vukovojac. Production Controller: Nicci Crawley. Supplement Production Controller: Simone Larché

Subscriptions – EU/Rest of World Subscription price per annum (3 volumes, 24 issues) £655, rest of world £735 (Surface mail) £880 (Airmail), or equivalent in any other currency. Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Magazines and sent to: The Subscription Department, Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 519 2455. Full details must accompany the payment. Subscribers from EC territories should add sales tax at the local rate.

Subscriptions – USA USA subscribers call toll free 1-800-221-2123 or send check/money order/credit card details to: Stockton Press, 345 Park Avenue South, 10th Floor, New York, NY 10010-1707; Tel: +1 212 689 9200, Fax: +1 212 689 9711. USA annual subscription rates (institutional/corporate): \$1170 (surface) \$1400 (airmail). Individual making personal payment: \$240.

British Journal of Pharmacology (ISSN 0007-1188) is published twice a month by Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel, NJ 07001, USA. Subscription price for institutions is \$1170 per annum (surface). 2nd class postage is paid at Rahway NJ. Postmaster: send address corrections to Macmillan Press Ltd, c/o Mercury Airfreight International Ltd, 2323 Randolph Avenue, Avenel NJ 07001.

Reprints of any article in this journal are available from Stockton Press, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 (0)1256 29242; Fax: +44 (0)1256 810526.

Copyright © 1996 Stockton Press ISSN 0007-1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Stockton Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$12.00 per copy is paid directly to CCC, 21 Congress St., Salem, MA 01970, USA. 0007 – 1188/96 \$12.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.

1997 KEYSTONE SYMPOSIA CONFERENCES

co	NFERENCE (MAX. ATTENDANCE)	SITE · DATE	ORGANIZERS
	Abstract Deadline: September 4,		istration Deadline: October 2, 1996
A1	Growth Control (800)	Keystone • 1/4-10	Charles J. Sherr and Tony Hunter
A2	Bone, Cartilage & Collagen: Growth & Differentiation (350)	Santa Fe • 1/7-12	John T. Potts, Jr., Stephen Krane and Henry Kronenberg
43	Ocular Cell and Molecular Biology (400)	Tamarron • 1/7-12	Steven E. Wilson and Joe G. Hollyfield
n	Molecular and Cellular Biology of Apicomplexan Protozoa (200)	Park City • 1/7-12	Carolyn Petersen and Michael W. White
12	Innate Immunity: Non-Clonal Host Defense Mechanisms (200)	Park City • 1/7-12	Gill Diamond, Anne H. Fortier and Albert Bendelac
A 4	B Lymphocytes in Health and Disease (400)	Steamboat Springs • 1/10-16	Maureen C. Howard, Norman R. Klinman and Max D. Cooper
J3	The Adipose Cell: Molecular Aspects of Differentiation, Gene Expression and Metabolic Regulation in the Normal Cell and Obese Models (200)	Park City • 1/15-21	Vincent C. Manganiello and Constantine Londos
J 4	Insulin Action & Secretion in NIDDM (200)	Park City • 1/15-21	Ira D. Goldfine and Sam Cushman
	Abstract Deadline: September 18,	1996 — Early Regi	istration Deadline: October 16, 1996
31	Evolution of Plant Development (600)	Taos • 1/20-26	Susan R. Wessler, Michael Freeling and Elliot M. Meyerowitz
15	Inflammation, Growth-Regulatory Molecules and Atherosclerosis (500)	Keystone • 1/20-26	Russell Ross and Michael A. Gimbrone, Jr.
16	Immunologic Aspects of Cardiovascular Disease (300)	Keystone • 1/20-26	Noel R. Rose, Ahvie Herskowitz and Fred P. Sanfilippo
32	Lipid Mediators: Recent Advances in Molecular Biology, Understanding of Regulation and Pharmacology (300)	Keystone • 1/26-31	Robert C. Murphy and Stephen M. Prescott
33	Tolerance and Autoimmunity (800)	Keystone • 1/27-2/2	Tak W. Mak, Hans Wigzell and Irving Weissman
	Abstract Deadline: October 1, 19	996 - Farly Registr	ration Deadline: November 1, 1996
21	Molecular Mechanisms in Alzheimer's Disease (400)	Tamarron • 2/1-6	Bruce A. Yankner and Allen D. Roses
17	RNA-Protein Interactions (300)	Taos • 2/1-6	Bert L. Semier and Peter Samow
8	Aminoacyl tRNA Synthetases in Biology & Disease (200)	Taos * 2/1-6	Susan A. Martinis, Karin Musier-Forsyth and Charles W. Carter, Ju
22	Cellular Immunology and the Immunotherapy of Cancer - III (400)	Copper Mtn • 2/1-7	Michael T. Lotze and Olivera J. Finn
3	Frontiers of NMR in Molecular Biology - V (600)	Taos • 2/6-11	Gerhard Wagner, Stephen W. Fesik and Stanley J. Opella
24	Hematopoiesis (400)	Tamarron • 2/10-16	David W. Golde and Judith C. Gasson
25	Molecular Mechanisms of Evolution: Structure, Function, Expression and Regulation of Genes and Proteins (350)	Santa Fe • 2/16-21	Dennis A. Powers, Franklin G. Berger, Caro-Beth Stewart and Douglas L. Crawford
26	Apoptosis and Programmed Cell Death (400)	Tamarron • 2/18-23	J. John Cohen and John A. Cidlowski
	Abstract Deadline: October 15, 19	996 - Farly Registi	ration Deadline: November 15, 1996
D1		Copper Mtn • 2/22-27	Richard B. Womer, Lee J. Helman and Frederic G. Barr
<u></u>		Santa Fe • 2/23-28	Larry R. Gerace, Christine Guthrie and Alan P. Wolffe
)3	Transposition and Site-Specific Recombination (350)	Santa Fe • 3/1-7	Jef D. Boeke, Nigel D.F. Grindley and Suzanne B. Sandmeyer
(1	Protein Folding, Modification and Transport in the Early Secretory Pathway (300)	Taos • 3/3-9	Randal J. Kaufman and Ari Helenius
K2	Processing of Peptide Hormones, Neurotransmitters, Growth Factors and Viral Proteins (300)	Taos • 3/3-9	Lloyd D. Pricker, Dennis Shields and Gary Thomas
)4	Germ Cell Differentiation (250)	Frisco • 3/12-17	Peter J. Donovan, Robert E. Braun and Tim B. Schedl
D 5	Discovery and Development of Novel Therapeutic Agents for the 21st Century (400)	Tamarron • 3/16-21	Simon Campbell, James A. Bristol and Eric M. Gordon
D6	Mucosal Immunity: Cellular and Molecular Cross-Talk at Mucosal Surfaces (350)	Santa Fe • 3/23-28	Marian R. Neutra and Martin F. Kagnoff
	Abstract Deadline: October 29, 1	1996 - Early Regis	tration Deadline: December 2,1996
31	The Role of Chemokines in Leukocyte Trafficking and Disease (400)	Copper Mtn • 3/31-4/5	Stephen W. Hunt, III, Steven L. Kunkel, John Westwick and Gregory J. LaRosa
K 3	Temporal & Spatial Determinants of Specificity in Signal Transduction (400)	Keystone • 3/31-4/6	Alan R. Saltiel and Frank McCormick
K 4	Signal Transduction by Cell Adhesion Receptors (400)	Keystone • 3/31-4/6	Rudolph L. Juliano and Ric Assoian
Ξ2	Molecular Biology of Muscle Development (450)	Snowmass • 4/1-6	Leslie A. Leinwand, Charles P. Ordahl and Robert J. Schwartz
	Metabolic Engineering in Transgenic Plants (400)	Copper Mtn • 4/6-11	Richard A. Dixon and Charles J. Arntzen
E3	AIDS Pathogenesis (500)	Keystone • 4/8-13	Ronald C. Desrosiers, George M. Shaw and Michael Emerman
_			
E3 E4 E5	Genetics of Human Cancer: Pathogenesis & Diagnosis (500)	Keystone • 4/13-19	Riccardo Dalla-Favera and Eric R. Fearon

If you have ever applied for or attended a Keystone Symposia conference, you will be sent registration information.

Otherwise, write, call, or e-mail us to receive more information.

Keystone Symposia • Drawer 1630 • Silverthorne, CO 80498

Phone: (800) 253-0685 or (970) 262-1230 • Fax: (970) 262-1525 • E-mail: keystone@symposia.com Visit our web site at http://www.colorado.net/symposia *All meetings are subject to change.

PREPARATION OF MANUSCRIPTS

Authors are strongly recommended to read the full Instructions to Authors and Nomenclature Guidelines for Authors (Br. J. Pharmacol. 1996, 117, 389-399) before submitting a manuscript for publication in the British Journal of Pharmacology. The manuscript and cover letter should be checked against the following list before mailing.

The original and one copy of the manuscript must be supplied. Manuscripts must be typed in double-line spacing on one side of A4 paper, in type not smaller than 12 characters per inch or 10 point. Both copies to include Tables and a set of labelled Figures. One set of Figures without numbers or letters is also to be included. The text to be arranged in the following subsections:

- Title—To have no more than 150 characters on a separate page, which should also include a Short Title (50 characters maximum) and the name and address of the author for correspondence.
- Summary—To be arranged in numbered paragraphs (Full Papers) or a single paragraph (Special Reports).
 —to include aims, principal results and conclusions.
 - -to include Key words (10 maximum) at end of summary.
- 3. Introduction—To contain concise statements of the problem and the aims of the investigation.
- Methods To have brief but adequate account of the procedures; full names of drugs (including those referred to by manufacturer's code), sources of drugs and statistical tests to be stated.
- Results—To have no repetition of data in Figures, Tables and text.
- Discussion Findings and conclusions to be placed in context of other relevant work.
 NB Simple repetition of results and unwarranted speculation are not acceptable.
- Acknowledgements Sources of support. Sources of drugs not widely available commercially.
- 8. **References**—All references in the text to be included in the Reference List and *vice versa*. References in alphabetical order with complete citations; Journals publishing 'in press' papers identified.

References to manuscripts submitted to other journals but not yet accepted are not allowed.

- 9. Tables—Each on a separate page and prepared in accordance with current requirements of the Journal.
- 10. Figures Both labelled and non-labelled Figures to be prepared in accordance with current requirements of the Journal (see *Instructions to Authors*, 1996, 117, 389-396) and provided with Figure Number and Authors' names on back (in pencil).
 - —each legend to be typed on a separate page and carrying keys to symbols.
 - —keys to symbols and histograms must not appear on the figures themselves, but in the respective legends.
 - —'box style' figures are not in keeping with the Journal style; line drawings etc must have only left-hand and bottom axes.
- 11. Manuscripts—To be accompanied by a declaration signed by each author that
 - (a) results are original
 - (b) approval of all persons concerned has been given to submit manuscripts for consideration (see also 12b)
 - (c) the same material is neither 'in press' (i.e. is in proof or has definitely been accepted for publication) nor under consideration elsewhere. Furthermore it will not be submitted or published elsewhere before a decision has been reached by the Editorial Board of the British Journal of Pharmacology and will not be submitted elsewhere if accepted by the British Journal of Pharmacology.
 - (d) Copyright assignment is included.
- 12. Cover letter To state clearly
 - (a) Corresponding author's full postal address, telephone, telex or Fax number
 - (b) where appropriate, that *either* ethical approval has been given for investigation or Company or Institutional permission to publish work has been received.
- 13. **Reminder**—Packaging to be sufficiently robust to protect Figures and to withstand mailing.

Failure to comply with *Instructions to Authors* may lead to substantial delays in processing, review and publication and may even jeopardize acceptance of the manuscript.

NOMENCLATURE

Authors are reminded that accepted receptor and associated terminology is laid out in *Nomenclature Guidelines for Authors*, as published in the *British Journal of Pharmacology*, Br. J. Pharmacol., 1996, 117, 397-399.

SPECIAL REPORTS

The purpose of *Special Reports* is to provide rapid publication for **new** and **important** results which the Editorial Board considers are likely to be of special pharmacological significance. *Special Reports* will have publication priority over all other material and so authors are asked to consider carefully the status of their work before submission.

In order to speed publication there is normally no revision allowed beyond very minor typographical or grammatical corrections. If significant revision is required, the Board may either invite rapid re-submission or, more probably, propose that it be re-written as a Full Paper and be re-submitted for consideration. In order to reduce delays, proofs of *Special Reports* will be sent to authors but essential corrections must reach the Production Office within 48 hours of receipt. Authors should ensure that their submitted material conforms exactly to the following requirements. In a covering letter, the authors should state clearly and briefly, why THEY consider the Report to be of special pharmacological significance and should therefore receive priority for publication as a Special Report.

special pharmacological significance and should therefore receive priority for publication as a Special Report.

Special Reports should normally occupy no more than two printed pages of the Journal; two illustrations (Figures or Tables, with legends) are permitted. As a guideline, with type face of 12 pitch and double-line spacing, a page of A4 paper could contain about 400 words. The absolute maximum length of the Special Report is 1700 words. For each Figure or Table, please deduct 200 words. The manuscript should comprise a Title page with key words (maximum of 10), a Summary consisting of a single short paragraph, followed by Introduction, Methods, Results, Discussion and References (maximum of 10). In all other respects, the requirements are the same as for Full Papers (see current 'Instructions to Authors').

British Journal of Pharmacology



Subscription Order Form

To: Stockton Press, Direct Marketing, Houndmills, Basingstoke, Hampshire, RG21 6XS, England Tel: +44 (0)1256 51898 Fax: +44 (0)1256 28339

*IMPORTANT NOTICE FOR EUROPEAN UNION CUSTOMERS

Customers resident in the European Union are liable to VAT/BTW/MOMS/TVA/MWST/FPA/IVA/TAV or equivalent when ordering. You must either:

a) write your VAT (or equivalent) number in the space provided or b) add tax at your country's rate to the total value of your order Customers receiving goods outside the European Union do not have to pay VAT

We welcome payment in your own currency, converted at the current rate.

1996 Subscription Rates

ISSN 0007 1188 One Year (24 Issues)

European Union* £665 Rest of the World £735

Customers receiving goods outside the European Unio Our UK VAT number is GB 199440621	n do not have to pay VAI				
Yes, please record my subscrip	tion to British Journal of	Pharmacology for one year (24 issues	s)		
I enclose a cheque for	I enclose a cheque for made payable to Macmillan Magazines				
VAT number (see notice above)					
Please charge	to my	Name (BLOCK CAPITALS)			
Credit Card Account No.		Position			
		Position			
Account Name		Address			
Account address 🔲 as opposite be	<u></u>				
specify	,				
		Postal/Zip Code			
		Country			
Signature		Tel:			
Expiry Date		Fax:	STOCKTON		

British Journal of	Pharmaco	logy 24 ISSUES PER YEAR	
Subscription Order Form To: Stockton Press, Journals Marketing 345 Park Avenue South, 10th Floor, NY 10010-1707. USA Tel: (212) 689 9200 Fax: (212) 689 9711 Toll Free: 800 221 2123	1996 Subscription R ISSN 0007 1188 European Union* Rest of the World Personal Rate	One Year (24 Issues) £665 \$1170 \$240 (payment by personal check or credit card only)	
☐ Yes, please record my subscription to British Journ ☐ I enclose a check for	nal of Pharmacology for one	Press	
☐ Please charge	Position	PITALS	
SignatureExpiry Date	Postal/Zip Code Country Tel:		

LIBRARY RECOMMENDATION FORM

To: Librarian/Library Acquisition Committee I have just reviewed a sample copy of the journal detailed overleaf entitled:

Please include it in your next serials review meeting with my recommendation. (Further sample copies are available from Stockton Press, Direct Marketing, Houndmills, Basingstoke Hampshire RG21 6XS, UK)							
I recommend the journal for the following reasons:							
Name: Position:							
Department:							
LIDDADY DECOMMENDATION FORM							
LIBRARY RECOMMENDATION FORM							
To: Librarian/Library Acquisition Committee I have just reviewed a sample copy of the journal detailed overleaf entitled:							
Please include it in your next serials review meeting with my recommendation. (Further sample copies are available from Stockton Press, Journals Marketing, 345 Park Avenue South, 10th Floor, NY 10010-1707. USA)							
I recommend the journal for the following reasons:							

Name: Position:

Department:

SPECIAL REPORTS

- D. Tolan, A.-M. Conway, L. Steele, S. Pyne & N.J. Pyne The identification of DL-threo dihydrosphingosine and sphingosine as novel inhibitors of extracellular signal-regulated kinase signalling in airway smooth muscle

 185
- J. Gras, J. Llenas, J.M. Palacios & D.J. Roberts The role of ketoconazole in the QTc interval prolonging effects of H₁-antihistamines in a guinea-pig model of arrhythmo-genicity
 187
- E.S.L. Faber, J.P. Chambers, R.H. Evans & G. Henderson Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro 189
- F. Plane & C.J. Garland Influence of contractile agonists on the mechanism of endothelium-dependent relaxation in rat isolated mesenteric artery 191

PAPERS

- I. Bresink, T.A. Benke, V.J. Collett, A.J. Seal, C.G. Parsons, J.M. Henley & G.L. Collingridge Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells 195
- M. Nakamura, T. Ando, M. Abe, K. Kumagai & Y. Endo Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice 205
- T. Unno, S. Komori & H. Ohashi Some evidence against the involvement of arachidonic acid in muscarinic suppression of voltage-gated calcium channel current in guinea-pig ileal smooth muscle cells

 213
- C.C. Tenn, J.M. Neu & L.P. Niles PK 11195 blockade of benzodiazepine-induced inhibition of forskolin-stimulated adenylate cyclase activity in the striatum 223
- X.-J. Yu & M.A. Moskowitz Neuropeptide Y Y₂ receptor-mediated attenuation of neurogenic plasma extravasation acting through pertussis toxin-sensitive mechanisms 229
- M.P. Carrasco, M.C. Sanchez-Amate, C. Marco & J.L. Segovia Evidence of differential effects produced by ethanol on specific phospholipid biosynthetic pathways in rat hepatocytes 233
- J. Gutkowska & P.W. Schiller Renal effects of TAPP, a highly selective μ -opioid agonist 239
- S. Komori, M. Iwata, T. Unno & H. Ohashi Modulation of carbachol-induced $[Ca^{2+}]_i$ oscillations by Ca^{2+} influx in single intestinal smooth muscle cells 245
- R.A. Cunha, P. Correia-de-Sá, A.M. Sebastião & J.A. Ribeiro Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides 253
- W.W. Lin & Y.T. Lee Pyrimidinoceptor-mediated activation of phospholipase C and phospholipase A₂ in RAW 264.7 macrophages 261
- X.F. Deng, S. Chemtob & D.R. Varma Characterization of α_{1D} -adrenoceptor subtype in rat myocardium, aorta and other tissues 269
- M.R. MacLean, R.A. Clayton, A.G.B. Templeton & I. Morecroft Evidence for 5-HT₁-like receptor-mediated vasoconstriction in human pulmonary artery 277
- A. Szallasi, M. Jonassohn, G. Acs T. Bíró, P. Acs, P.M. Blumberg & O. Sterner The stimulation of capsaicin-sensitive neurones in a vanilloid receptor-mediated fashion by pungent terpenoids possessing an unsaturated 1,4-dialdehyde moiety 283

- P.G. Knott, P.J. Henry, A.S. McWilliam, P.J. Rigby, L.B. Fernandes & R.G Goldie Influence of parainfluenza-1 respiratory tract viral infection on endothelin receptor-effector systems in mouse and rat tracheal smooth muscle 291
- R. Fernández, R. Sabater, J.A. Sáez, R. Montes, F. Alba & J.M.R. Ferrer Mediation by neurotensin-receptors of effects of neurotensin on self-stimulation of the medial prefrontal cortex 299
- B.R. Tuladhar, B. Costall & R.J. Naylor Pharmacological characterization of the 5-hydroxytryptamine receptor mediating relaxation in the rat isolated ileum 303
- C. Plumpton, C.J. Ferro, W.G. Haynes, D.J. Webb & A.P. Davenport The increase in human plasma immunoreactive endothelium but not big endothelium-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044
- S. Phenna, E. Carpenter, C. Peers, S. Maudsley & J.P. Gent Inhibition of Ca²⁺-sensitive K⁺ currents in NG 108-15 cells by substance P and related tachykinins 315
- N.D. Holliday & H.M. Cox The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y_1 receptor 321
- E. Glusa & A. Roos Endothelial 5-HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine 330
- L.M. Shuba, T. Asai, S. Pelzer & T.F. McDonald Activation of cardiac chloride conductance by the tyrosine kinase inhibitor, genistein 335
- A. Kawabata & T. Hata Attenuation by prolonged nitric oxide synthase inhibition of the enhancement of fibrinolysis caused by environmental stress in the rat

 346
- G. Kolios, D.A.F. Robertson, N.J. Jordan, A. Minty, D. Caput, P. Ferrara & J. Westwick Interluekin-8 production by the human colon epithelial cell line HT-29: modulation by interleukin-13 351
- P. Vigne, P. Pacaud, V. Urbach, E. Feolde, J.P. Breittmayer & C. Frelin The effect of PPADS as an antagonist of inositol (1,4,5)trisphosphate induced intracellular calcium mobilization 360
- F. Tomoda, R.A. Lew, A.I. Smith, A.C. Madden & R.G. Evans Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits.
- P.S. Widdowson, M. Farnworth, R.B. Moore, D. Dunn & I. Wyatt Evidence for mediation of L-2-chloropropionic acid-induced delayed neuronal cell death by activation of a constitutive nitric oxide synthase

 374
- H. Pickering, S. Sword, S. Vanhoff, R. Jones & D. Sugden Analogues of diverse structure are unable to differentiate native melatonin receptors in the chicken retina, sheep pars tuberalis and *Xenopus* melanophores 379
- A. Ziyyat, B.-L. Zhang & D. Benzoni Interactions between nitric oxide and prostanoids in isolated perfused kidneys of the rat 388
- A.J. Forhead, K. Whybrew, P. Hughes, F. Broughton Pipkin, M. Sutherland & A.L. Fowden Comparison of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition in pregnant sheep during late gestation 393



- A. Lindén Increased interleukin-8 rélease by β -adrenoceptor activation in human transformed bronchial epithelial cells 402
- I. Marshall, R.P. Burt, G.M. Green, M.B. Hussain & C.R. Chapple Different subtypes of α_{1A} -adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053
- P.D. Marley & K.A. Thomson Inhibition of nicotinic responses of bovine adrenal chromaffin cells by the protein kinase C inhibitor, Ro 31-8220 416
- R.L.C. Handy, H.L. Harb, P. Wallace, Z. Gaffen, K.J. Whitehead & P.K. Moore Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM) *in vitro*: antinociceptive and cardiovascular effects 423

- E. Lilley & A. Gibson Antioxidant protection of NO-induced relaxations of the mouse anococcygeus against inhibition by superoxide anions, hydroquinone and carboxy-PTIO 432
- S.-F. Luo, C.-T. Tsai, W.-B. Wu, S.-L. Pan, Y.-J. Tsai & C.-M. Yang Pharmacological and functional characterization of bradykinin receptors in canine cultured tracheal epithelial cells 439
- M.J. Pierce, J.A. Warner, M.R. Munday & P.T. Peachell Regulation of human basophil function by phosphatase inhibitors 446